Joseph Jacob outlines evidence supporting the use of a new tool measuring vessel parameters on computed tomography scans to predict mortality risk in patients with idiopathic pulmonary fibrosis (5:24).
Funding for independent interviews at ATS 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.